Home › Parkinson's Disease › NCT02071134
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Key Inclusion Criteria: * Meets criteria established in locally applicable Vercise System Direction for Use * At least 18 years old Key Exclusion Criteria: * Meets any contraindication in the Vercise System locally applicable Directions for Use Subjects with significant cognitive or psychiatric impairment may be excluded in the evaluation of GXT.
About the study
The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease.
The utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated.
Additionally, the utilization of the DBS Illumina 3D feature that may be used for the programming of patients with Boston Scientific's Vercise DBS Systems is also evaluated.
What is being tested
- Deep Brain Stimulation (DBS) (device)
Sponsor: Boston Scientific Corporation · Participants: 1,500 · Started: Mar 4, 2014
Contact the study team
- Heleen Scholtes · Phone: 855-213-9890
- Alison Lewis · Phone: 855-213-9890
Official record on ClinicalTrials.gov — NCT02071134
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.